

UNITED STATE MEPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	
09/508,09	95 03/16/0	0 ZUCHT		· H	P65141US0
			\neg	EXAMINER	
000136		HM12/083()		
JACOBSON HOLMAN PLLC			MOFZIE.F		
400 SEVENTH STREET N.W.			ART UNIT	PAPER NUMBER	
SUITE 600 WASHINGTO))N DC 20004			1653 DATE MAILED:	q
					08/30/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. **09/508.095**

Applicant(s)

FORSSMANN

Examiner

F. MOEZIE

Art Unit 1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --P riod for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 3/16/00 and 8/21/01 2a) This action is **FINAL**. 2b) X This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims 4) X Claim(s) 1 and 3-5 is/are pending in the application. 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) U Claim(s) is/are allowed. 6) Claim(s) ______ is/are rejected. _____is/are objected to. 7) (Claim(s) 8) X Claims 1 and 3-5 are subject to restriction and/or election requirement. **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on _____ is/are objected to by the Examiner. 11)□ The proposed drawing correction filed on is: a)□ approved b)□ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. U Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20) Other:

DETAILED ACTION

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4 and 5, drawn to peptide sequences.

Group II, claim 5, drawn to nucleic acid coding sequences.

2. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: they lack the same technical features, amino acids for peptides do not correspond to the special technical features for nucleic acid sequences.

In the event that Group I invention is elected, applicant is further required to comply with a second election requirement as follows: to elect **one peptide sequence** from among the peptide sequences designated as SEQ ID NO:1-24, cited in claim 5. The sequences lack a special technical features because each peptide sequence has its special length and its special amino acid arrangement(s) in its sequence which does not correspond to other peptide sequences.

In the event that Group II invention is elected, applicant is further required to comply with a second election requirement as follows: to elect **one nucleic acid encoding sequence** from among the various sequences encompassed by claim 3. The sequences lack a special

Application/Control Number: 09/508,095

Art Unit: 1653

technical features because each nucleic acid encoding sequence has its special length and arrangement which does not correspond to other sequences.

Applicant is advised that the reply to this requirement to be complete must include an election of: a) Invention I or II followed by b) an election of a single peptide sequence or nucleic acid encoding sequence, to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F.T. Moezie whose telephone number is (703) 305-4508 or Dr. LOW (SPE) at 308-2923.

J. J. Moegas

Page 3